BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, has announced a collaboration to manufacture BiVictriX’s antibody-drug conjugates (ADC) with Abzena Limited (Abzena), a partner research organization for integrated discovery to cGMP manufacturing solutions for biologics.
 
The collaboration will allow BiVictriX to cost-effectively manufacture its anti-cancer ADCs for use in pre-clinical models without the need for extensive manufacturing facilities of its own. ADC production will be carried out in two cycles: the first cycle being ADC manufacturing for proof-of-concept studies; and the second cycle will cover ADC lead selection and optimization. This collaboration has been secured just three months after BiVictriX listed on the AIM market of the London Stock Exchange, raising gross proceeds of £7.5 million ($10.1 million).
 
Tiffany Thorn, chief executive of BiVictriX Therapeutics plc, commented, “Abzena is world-renowned for possessing the expertise and capabilities to develop and manufacture antibody-drug conjugates to the highest standards. Utilizing Abzena’s extensive knowledge in the field will be highly valuable as we look to expedite the development of our lead candidate, BVX001, and additional pipeline candidates towards achieving key pre-clinical milestones. We look forward to this initial collaboration marking the beginning of a successful and ongoing partnership with Abzena.”
 
Campbell Bunce, chief scientific officer of Abzena, said, “We’re delighted to be able to support the development of BiVictriX’s ADCs through our expert development, characterization and manufacturing services. BiVictriX’s “twin antigen” targeting Bi-Cygni therapeutics present an innovative approach to targeting cancer cells and we hope to support their development as best we can.”